
BioStem Technologies, Inc.
Nasdaq · Biological Products, (No Diagnostic Substances)
Company Overview
A concise company profile alongside the latest public filing activity.
BioStem Technologies develops and manufactures placental tissue-based allografts derived from the amniotic membrane and umbilical cord, which are used in wound care and other regenerative medicine applications. The company processes donated birth tissue into products marketed to healthcare providers for treating chronic wounds and other clinical conditions.
Company profile sourced from SEC filings.
Corporate Insider Trades
Open-market purchases and sales by directors, officers, and other company insiders.
| Insider | Type | Value | Shares / Price | Date |
|---|---|---|---|---|
| Matuszewski JasonChief Executive Officer | Sell | $14K | 14,300at $1.00 | Nov 17, 2026 |
Source: SEC EDGAR Form 4 filings
Congressional Trades
Recent disclosures by members of the U.S. House and Senate.
Source: Senate eFD and House Clerk STOCK Act disclosures
Get notable BSEM activity by email
Free alerts for the insider and congressional trades worth watching.
For informational purposes only, not investment advice. Filings can be delayed, corrected, or amended. Trading activity alone does not predict future performance.